Original Articles

Five years survival and quality of life after radical nephrectomy: a descriptive single-center study

Adryansyah Can , Ginanda Putra Siregar, Bungaran Sihombing, Fauriski Febrian Papriska, Syah Mirsa Warli

Adryansyah Can
Department of Urology, Faculty of Medicine Universitas Sumatera Utara-Universitas Sumatera Utara Hospital, Medan, Indonesia. Email: gregadryan@gmail.com

Ginanda Putra Siregar
Department of Urology, Faculty of Medicine Universitas Sumatera Utara-Universitas Sumatera Utara Hospital, Medan, Indonesia

Bungaran Sihombing
Department of Urology, Faculty of Medicine Universitas Sumatera Utara-Universitas Sumatera Utara Hospital, Medan, Indonesia

Fauriski Febrian Papriska
Department of Urology, Faculty of Medicine Universitas Sumatera Utara-Universitas Sumatera Utara Hospital, Medan, Indonesia

Syah Mirsa Warli
Department of Urology, Faculty of Medicine Universitas Sumatera Utara-Universitas Sumatera Utara Hospital, Medan, Indonesia
Online First: June 22, 2021 | Cite this Article
Can, A., Siregar, G., Sihombing, B., Papriska, F., Warli, S. 2021. Five years survival and quality of life after radical nephrectomy: a descriptive single-center study. Indonesia Journal of Biomedical Science 15(1): 75-79. DOI:10.15562/ijbs.v15i1.306

Introduction: Health-related quality of life (QoL) is an increasingly important factor in examining the benefits of different cancer treatments, such as radical nephrectomy for those with a renal mass presumed to be renal cell carcinoma (RCC). This study evaluates five years of survival rate, and quality of life of the patient after radical nephrectomy in our center.

Methods: This descriptive longitudinal study included thirty patients who were diagnosed as having renal mass in Urology division of H. Adam Malik General Hospital between January 2014 and December 2015. All patients were completely followed up for 5 years or until the patient died. We used a translated and validated Indonesian written European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ-C30) to assess the patient’s quality of life.

Results: Overall, 5-years survival of kidney tumor patients was 100%, 66.67%, 50%, 8.33%, respectively for stages 1 to 4. We found a sharp decrease in the cumulative survival rate of stage IV group in the first 24 months compared to the first 12 months, from 66.67% to 25%. This pattern of decrease was not found in the other group of stages. Overall, patients' quality of life had increased in the first three years postoperatively and decreased in the two years afterward. These fluctuations consistently occur in all groups. All of the groups had reached the maximum quality of life at the third year postoperatively.

Conclusion: Stage I renal cell carcinoma patients showed the best five-year survival rate and quality of life. The quality of life for all groups inclined for the first three years after surgery and decline consistently afterward.


van Oostenbrugge TJ, Fütterer JJ, Mulders PFA. Diagnostic Imaging for Solid Renal Tumors: A Pictorial Review. Kidney cancer (Clifton, Va). 2018;2(2):79–93. Available from: https://pubmed.ncbi.nlm.nih.gov/30740580

Tan WS, Berg S, Cole AP, Krimphove M, Marchese M, Lipsitz SR, et al. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI cancer Spectr. 2019;3(1):pkz003–pkz003. Available from: https://pubmed.ncbi.nlm.nih.gov/31360891

Kunath F, Schmidt S, Krabbe L-M, Miernik A, Dahm P, Cleves A, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane database Syst Rev. 2017;5(5):CD012045–CD012045. Available from: https://pubmed.ncbi.nlm.nih.gov/28485814

Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9(1–6):461–73. Available from: https://pubmed.ncbi.nlm.nih.gov/22112490

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. Available from: http://dx.doi.org/10.3322/caac.20138

Yang C, Liao Z. Comparison of Radical Nephrectomy and Partial Nephrectomy for T1 Renal Cell Carcinoma: A Meta-Analysis. Urol Int. 2018;101(2):175–83. Available from: http://dx.doi.org/10.1159/000490576

Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical Nephrectomy for Renal Cell Carcinoma: Long-Term Results and Prognostic Factors on a Series of 328 Cases. Eur Urol. 1997;31(1):40–8. Available from: http://dx.doi.org/10.1159/000474416

Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol. 2008/11/13. 2009;181(1):55–62. Available from: https://pubmed.ncbi.nlm.nih.gov/19012918

Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–52. Available from: http://dx.doi.org/10.1016/s0094-0143(03)00056-9

Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005;6(1):7–18. Available from: http://dx.doi.org/10.1007/s11934-005-0062-x

Reese AC, Whitson JM, Meng M V. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol Semin Orig Investig. 2013;31(7):1305–9. Available from: http://dx.doi.org/10.1016/j.urolonc.2011.12.006

Gangadaran SGD. Current Management Options in Metastatic Renal Cell Cancer. Oncol Rev. 2017;11(2):339. Available from: https://pubmed.ncbi.nlm.nih.gov/28680539

Ljungberg B. The Role of Metastasectomy in Renal Cell Carcinoma in the Era of Targeted Therapy. Curr Urol Rep. 2012;14(1):19–25. Available from: http://dx.doi.org/10.1007/s11934-012-0293-6

Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008/07/17. 2008;180(3):873–8. Available from: https://pubmed.ncbi.nlm.nih.gov/18635225

Yücel ÖB, Tunç HM, Başaran M, Aras N. 22-year survival following radical nephrectomy and several metastasectomies in a case of renal cell carcinoma. Turkish J Urol. 2017/04/18. 2017;43(2):216–9. Available from: https://pubmed.ncbi.nlm.nih.gov/28717549

Permpongkosol S, Bagga HS, Romero FR, Sroka M, Jarrett TW, Kavoussi LR. Laparoscopic Versus Open Partial Nephrectomy for the Treatment of Pathological T 1 N 0 M 0 Renal Cell Carcinoma: A 5-Year Survival Rate. J Urol. 2006;176(5):1984–9. Available from: http://dx.doi.org/10.1016/j.juro.2006.07.033

Rampersaud EN, Klatte T, Bass G, Patard J-J, Bensaleh K, Böhm M, et al. The effect of gender and age on kidney cancer survival: Younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol Semin Orig Investig. 2014;32(1):30.e9-30.e13. Available from: http://dx.doi.org/10.1016/j.urolonc.2012.10.012

Thiel DD, Davidiuk AJ, Broderick GA, Arnold M, Diehl N, Tavlarides A, et al. Comparison of patient-reported quality of life outcome questionnaire response rates between patients treated surgically for renal cell carcinoma and prostate carcinoma. BMC Urol. 2015;15:58. Available from: https://pubmed.ncbi.nlm.nih.gov/26126615

Bergman J, Gore JL, Singer JS, Anger JT, Litwin MS. Readability of Health Related Quality of Life Instruments in Urology. J Urol. 2010;183(5):1977–81. Available from: http://dx.doi.org/10.1016/j.juro.2009.12.107

Gazmararian JA. Health Literacy Among Medicare Enrollees in a Managed Care Organization. JAMA. 1999;281(6):545. Available from: http://dx.doi.org/10.1001/jama.281.6.545

Sitlinger A, Zafar SY. Health-Related Quality of Life: The Impact on Morbidity and Mortality. Surg Oncol Clin N Am. 2018/07/21. 2018;27(4):675–84. Available from: https://pubmed.ncbi.nlm.nih.gov/30213412

Reviewer Guidance: Review of Human Pregnancy Outcome Data [Internet]. PsycEXTRA Dataset. Test accounts; 1999. Available from: http://dx.doi.org/10.1037/e330092004-001

Parker PA, Swartz R, Fellman B, Urbauer D, Li Y, Pisters LL, et al. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. J Urol. 2012/01/15. 2012;187(3):822–6. Available from: https://pubmed.ncbi.nlm.nih.gov/22245327

Quinten C, Coens C, Ghislain I, Zikos E, Sprangers MAG, Ringash J, et al. The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. Eur J Cancer. 2015;51(18):2808–19. Available from: http://dx.doi.org/10.1016/j.ejca.2015.08.027

Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865–71. Available from: http://dx.doi.org/10.1016/s1470-2045(09)70200-1

Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia. Jpn J Clin Oncol. 2011;41(4):519–29. Available from: http://dx.doi.org/10.1093/jjco/hyq243

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. Available from: http://dx.doi.org/10.3322/caac.21166

Krabbe L-M, Bagrodia A, Margulis V, Wood CG. Surgical management of renal cell carcinoma. Semin Intervent Radiol. 2014;31(1):27–32. Available from: https://pubmed.ncbi.nlm.nih.gov/24596437

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019;75(5):799–810. Available from: http://dx.doi.org/10.1016/j.eururo.2019.02.011

Tsui K-H, Shvarts O, Smith Rb, Figlin Ra, Dekernion Jb, Belldegrun A. Prognostic Indicators For Renal Cell Carcinoma: A Multivariate Analysis Of 643 Patients Using The Revised 1997 Tnm Staging Criteria. J Urol. 2000;163(4):1090–5. Available from: http://dx.doi.org/10.1016/s0022-5347(05)67699-9

No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0